Skip to main content
Caplight Logo









MOMA Therapeutics

MOMA Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://momatx.com/

Last Round

Series B

May 10, 2022

Total Funding Raised

$236M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

MOMA Therapeutics is a biotechnology company that discovers and develops precision medicines by targeting molecular machines that drive human disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

precision medicinedrug discoverymolecular machinessmall-molecule therapeuticsoncologyAI drug discoverycomputational biologybiotechstructural biologyundruggable targetsin silico drug discoverypharma collaborationclinical-stage biotechdrug discovery platformAI-native biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MOMA Therapeutics Comparables

Compare MOMA Therapeutics with similar companies based on industry and business-model similarity.

MOMA Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Relay Therapeutics
81%
Foghorn Therapeutics
78%
Bayer AG
77%

MOMA Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 10, 2022
Series AApr 15, 2020

Key People

Founding team and executive leadership

Asit Parikh

President And Chief Executive Officer At MOMA Therapeutics

Executive Team

MOMA Therapeutics Investors

Notable investors and investment history

MOMA Therapeutics investors
InvestorRounds
S32Series B
LifeSci Venture PartnersSeries B
Creacion VenturesSeries B, Series A
Cormorant Asset ManagementSeries B, Series A
Goldman Sachs Asset Management Private EquitySeries B
Invus OpportunitiesSeries B
Alexandria Venture InvestmentsSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 17, 2026

    Monthly visitors increased 42% MoM, reaching 2K.

  • Apr 25, 2025

    Three presentations scheduled for the 2025 AACR Annual Meeting in Chicago.

MOMA Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

MOMA Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about MOMA Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range42
Year Founded2020
Last FundingMay 10, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?